Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Poseidon Bio has developed an innovative modular technology platform based on an engineered human protein scaffold that can generate TCEs with a novel geometry to overcome the problems of current antibody-based immunotherapies.
Induced pluripotent stem cell technology is a promising, rapidly evolving field with the potential to transform cell-based therapeutics across a range of disease areas that have significant unmet medical needs.
Combined Therapeutics’ proprietary messenger RNA multi-organ protection platform can encode antigens and adjuvants alike with high tissue specificity for better efficacy and safety profiles.
BioCanRx is leading the way in the translation, manufacture and adoption of immunotherapies in Canada to ensure that Canadian patients have access to this powerful therapeutic approach via clinical trials.
MultiOmic Health is using a data-driven AI-enabled approach to develop tailored therapeutics for specific subpopulations of patients with metabolic syndrome-related conditions, which affect around half of the adult population worldwide.
Using its innovative SAFEPATH platform, which integrates cheminformatics and bioinformatics approaches, the AI-driven drug-turnaround company Ignota Labs is on a mission to understand the mechanisms of drug toxicity, rescue promising assets with previous safety issues, and get them to the clinic in record time.
SOPHiA GENETICS is untangling the multimodal complexities that have blunted the potential for artificial intelligence (AI)-driven analytics to accelerate drug development.
The clinical success of biologics is often hindered by a lack of safe, targeted delivery systems. SiVEC Biotechnologies aims to change this with its groundbreaking BactPac platform.
By detecting and targeting myeloid-dependent immune suppression, Bectas Therapeutics is on a mission to realize the full potential of cancer immunotherapies.
Bio-Sourcing is developing innovative solutions that combine cutting-edge gene-editing and nuclear-transfer technologies to up-scale the production of biopharmaceuticals while lowering carbon emissions and costs.
PROVIREX is developing first-in-class advanced therapies that may offer the chance of a cure for people with life-threatening persistent viral infections.
Aleta Biotherapeutics is using its novel technology platform to develop bespoke, multi-antigen-targeting biologics for a diverse range of indications, including B-cell cancers and solid tumors, improving outcomes in patient populations with high unmet need.
Current guidelines recommend transdermal delivery of testosterone for post-menopausal women seeking treatment for hypoactive sexual desire disorder. Medherant’s TEPI patch has been developed to fill this unmet medical need.
Transcenta is employing its unique, cutting-edge discovery technology to develop antibody-based therapies that address unmet medical needs in oncology, immunology and inflammation.
With its innovative VECTrans platform, Vect-Horus is enabling targeted drug delivery across the blood–brain barrier, potentially transforming the treatment of neurodegenerative disorders.
European biotech company Cellis has developed breakthrough platform technology to overcome the limitations of current solid-tumor treatments and provide life-changing therapies for cancer patients, advancing the field of precision oncology.
UK-based DefiniGEN has developed iPSC-derived cell lines that can replace primary human hepatocytes for toxicity testing and accelerate the development of novel liver-targeted therapeutics.
